It's time to better understand the brain-computer interface market

In 2026, brain-computer interfaces are hot, and they are finally turning into products people can buy.

We've found a lot of interesting signals. For example, China approved Neuracle's NEO, the first brain implant cleared for commercial sale. And Merge Labs, co-founded by Sam Altman, raised a $252M seed round with OpenAI among its investors. Approvals are arriving, and the biggest names in AI want a seat at the table.

Here, we'll look at what these approvals and rounds really change, why China is moving so fast, and which parts of the market are closest to real revenue.

BCIs exist because some problems are brutal. People with ALS lose their voice. People with spinal injuries lose the use of their hands.

But patients aren't the only ones in pain. Neurosurgeons, rehab clinics, research labs, headphone brands, and the teams building decoders all face their own problems. We go through each group and rank the issues that matter most to them.

That way, you can build or back a product for a problem someone will actually pay to fix.

Implants paid per procedure, lab equipment, rehab sessions billed by clinics, consumer headsets, and sensor licenses for headphone brands: BCI companies make money in very different ways.

We compare these models side by side. An implant can cost around $200K all in, but it needs a surgeon, a hospital, and a payer. A headset sells for a few hundred dollars, but many users stop wearing it after a few weeks.

You'll see who pays at each step and where the margins really sit, so you don't bet on a device that works but never gets paid for.

We give you a realistic growth rate for the BCI market. But a number alone doesn't tell you much, so we also explain what would make that growth happen.

Some drivers are clear: better AI decoders, the first approval for sale in China, and bigger funding rounds. Others build up over time. Each new payment code makes the next one easier to win. Each new user adds brain data that improves the decoder for everyone.

Before building or investing, you should know what has to happen for brain interfaces to reach many more patients, and who will pay for them.

Neuracle won the first approval to sell a brain implant, and BrainCo sells EEG headbands to more than 150,000 users. But they are only two pieces of a much wider BCI market.

Many of the most interesting startups rarely make headlines. Some build ultrasoft electrodes, others decode speech, sell arrays to research labs, or help stroke survivors move their hands again. They're worth watching.

BCIs aren't one kind of business. A brain implant, a focus headband, and a lab amplifier have different buyers, different rules, and very different timelines. So the companies are hard to compare, and the good ones are easy to miss.

That's why we share the market grids and ecosystem maps we've built, so you can see who does what and where the market is moving.

BrainCo, g.tec, StairMed… a few BCI companies are pulling ahead, each for a different reason.

Some already sell at scale, like EEG wearables and stroke rehab systems used in many countries. Others have raised large rounds for implants that still need approval. Attention and funding are not the same as a proven business, and we show where each model really stands.

We'll look at how BCI companies earn revenue while their long-term implant matures, and why real daily use counts more than lab records.